alzAPOE therapeutics change feed
Snapshot

Theses

The bets, not the molecules. A thesis is a claim about why Alzheimer's happens and what would change it — one that could turn out to be wrong; therapeutics are downstream artifacts of one. Evidence attaches here, so a thesis can carry a literature for years before any drug exists — 2 of the 7 below have no tracked therapeutic at all, and 4 have nothing in human trials. Those are positions this project holds, not rows waiting to be filled in.

APOE is the lens here, not the boundary. Most of these bets are about APOE biology directly; one is a drug whose target is something else entirely, tracked because APOE genotype decides who it helps and who it endangers; and Context marks an approach where APOE is incidental or simply not established. Each row says which it is. Ordered most advanced first.

1 source is not reporting cleanly — changes may be missingeuropepmc STALE

Changes that would have come from the sources below are absent from this feed. Absence here means “not observed”, not “did not happen”.

  • Europe PMC (europepmc, daily) — last successful fetch (2 days ago), last run status ok — past its staleness threshold.
  1. ObservationA phenomenon has been noted.
  2. Target validationA causal role has been tested in models.
  3. Tool compoundA molecule engages the target but is not developable.
  4. Development candidateA specific therapeutic is in preclinical development.
  5. ClinicalAt least one therapeutic is in human trials.

Maturity is an ordered scale, shaded along one hue that deepens with the ladder. It is curated, not derived: a thesis with no therapeutics still has a maturity, and two of the theses below sit lower than their molecules would suggest because those molecules are research tools rather than development candidates.

  1. ClinicalAPOE-stratified

    APOE genotype selects responders and governs risk; the therapeutic itself targets something else

    4 tracked therapeuticsfurthest stage approved

  2. ClinicalContext

    Metabolic dysfunction and impaired brain insulin signalling contribute to Alzheimer's; GLP-1 receptor agonism is protective

    1 tracked therapeuticfurthest stage phase 3

  3. ClinicalAPOE mechanism

    APOE4 is a loss of protective function; supplying a protective APOE variant compensates

    4 tracked therapeuticsfurthest stage phase 1

  4. Development candidateAPOE mechanism

    APOE4 is a gain of toxic function; lowering it in the CNS is protective

    2 tracked therapeuticsfurthest stage preclinical

  5. Target validationAPOE mechanism

    A specific APOE activity is harmful rather than APOE quantity; neutralise that activity while sparing physiological function

    2 tracked therapeuticsfurthest stage preclinical

  6. Target validationAPOE mechanismprovisional

    APOE4 is poorly lipidated; restoring lipidation (e.g. via ABCA1) is protective

    0 tracked therapeutics

    • No therapeutic — watched on the mechanism

  7. ObservationAPOE mechanismprovisional

    APOE4 drives blood–brain-barrier breakdown and cerebral amyloid angiopathy; protecting the neurovascular unit is protective

    0 tracked therapeutics

    • No therapeutic — watched on the mechanism

A therapeutic can appear under more than one thesis. LX1020 is listed twice on purpose: one AAV construct that both supplies APOE2 and suppresses APOE4 with a miRNA, hedging across two claims that contradict each other. Forcing it into one would be a guess about the sponsor's intent, so both memberships are recorded and each carries a note.